Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

BMC Health Services Research

Nikos Maniadakis¹  Georgia Kourlaba²  Christos Verras³  Andreas Melidonis³  Charalampos Tzanetakos¹ 

[1] Department of Health Services Organisation and Management, National School of Public Health, 196 Alexandras Avenue, 11521 Athens, Greece;Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), “Aghia Sophia” Children’s Hospital, Athens, Greece;Diabetes Center, Tzanio General Hospital, Piraeus, Greece

关键词: Greece;    Type 2 diabetes;    Liraglutide;    Cost-effectiveness;   

Others  :  1126242
DOI  :  10.1186/1472-6963-14-419

 received in 2014-06-20, accepted in 2014-09-15,  发布年份 2014

【 摘 要 】

Background

To evaluate the long-term cost-effectiveness of liraglutide versus sitagliptin or exenatide, added to oral antidiabetic drug mono- or combination therapy respectively, in patients with Type 2 diabetes in Greece.

Methods

The CORE Diabetes Model, a validated computer simulation model, was adapted to the Greek healthcare setting. Patient and intervention effects data were gathered from a clinical trial comparing liraglutide 1.2 mg once daily vs. sitagliptin 100 mg once daily, both combined with metformin, and a clinical trial comparing liraglutide 1.8 mg once daily vs. exenatide 10 μg twice daily, both as add-on to metformin, glimepiride or both. Direct costs were reported in 2013 Euros and calculated based on published and local sources. All future outcomes were discounted at 3.5% per annum, and the analysis was conducted from the perspective of a third-party payer in Greece.

Results

Over a patient’s lifetime, treatment with liraglutide 1.2 mg vs. sitagliptin drove a mean increase in discounted life expectancy of 0.13 (SD 0.23) years and in discounted quality-adjusted life expectancy of 0.19 (0.16) quality-adjusted life years (QALYs), whereas therapy with liraglutide 1.8 mg vs. exenatide yielded increases of 0.14 (0.23) years and 0.19 (0.16) QALYs respectively. As regards lifetime direct costs, liraglutide 1.2 mg resulted in greater costs of €2797 (€1468) versus sitagliptin, and so did liraglutide 1.8 mg compared with exenatide (€1302 [€1492]). Liraglutide 1.2 and 1.8 mg doses were associated with incremental cost effectiveness ratios of €15101 and €6818 per QALY gained, respectively.

Conclusions

Liraglutide is likely to be a cost-effective option for the treatment of Type 2 diabetes in a Greek setting.

【 授权许可】

   
2014 Tzanetakos et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Chen L, Magliano DJ, Zimmet PZ: The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol 2012, 8:228-236.
• [2]Williams R, Van Gaal L, Lucioni C, Board C-A: Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002, 45:S13-S17.
• [3]Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C: The epidemiology of Type 2 diabetes mellitus in Greek adults: the ATTICA study. Diabet Med 2005, 22:1581-1588.
• [4]International Diabetes Federation: IDF Diabetes Atlas. 6th edition. Brussels, Belgium: International Diabetes Federation; 2013. Accessed March 30, 2014 [http://www.idf.org/diabetesatlas webcite]
• [5]Athanasakis K, Ollandezos M, Angeli A, Gregoriou A, Geitona M, Kyriopoulos J: Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost. Diabet Med 2010, 27:679-684.
• [6]Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
• [7]Hellenic Diabetes Association: Management guidelines for a diabetic patient. Accessed September 15, 2013 [http://www.ede.gr/ webcite]
• [8]Bode B: An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 2012, 97:27-42.
• [9]Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004, 20(Suppl 1):S27-S40.
• [10]Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004, 20(Suppl 1):S5-S26.
• [11]Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M, Group L-D-S: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
• [12]Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, Group L-S: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
• [13]Liatis S, Thomakos P, Papaoikonomou S, Papazafeiropoulou A, Giannakopoulos N, Karagiaouri E, Sotiropoulos A, Bousboulas S, Melidonis A, Pappas S, Katsilambros N: Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006). Exp Clin Endocrinol Diabetes 2009, 117:505-510.
• [14]Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R, Liraglutide E, Action in Diabetes 5 met SUSG: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
• [15]Greek Ministry of Health: Drug Price Bulletin. Accessed September 15, 2013 [http://www.yyka.gov.gr/ webcite]
• [16]Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J: Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. Clin Ther 2012, 34:446-456.
• [17]Souliotis K, Papavasilopoulou M, Konstantinidou C, Spanakis ΑΜ, Apostolakis Μ, Iatrou C: Insurance coverage for the treatment of patients with chronic renal insufficiency. Adoption of economic assessment by the Institute of Social Insurance (IKA). Arch Hell Med 2009, 26(5):668-677.
• [18]Kaitelidou D, Ziroyanis PN, Maniadakis N, Liaropoulos LL: Economic evaluation of hemodialysis: implications for technology assessment in Greece. Int J Technol Assess Health Care 2005, 21:40-46.
• [19]Kourlaba G, Fragoulakis V, Maniadakis N: Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. Appl Health Econ Health Policy 2012, 10:261-271.
• [20]Kourlaba G, Fragoulakis V, Maniadakis N: Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. Appl Health Econ Health Policy 2012, 10:331-342.
• [21]Sidiropoulos S: Estimating the Cost of Renal Transplantation in Greece. Thesis: University of Macedonia, Business Administration Department; 2009.
• [22]Hellenic Statistical Authority (EL. STAT.): Inflation rates. Accessed September 30, 2013 [http://www.statistics.gr/portal/page/portal/ESYE webcite]
• [23]Davies MJ, Chubb BD, Smith IC, Valentine WJ: Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med 2012, 29:313-320.
• [24]World Health Organisation (WHO): Choosing interventions that are Cost Effective (WHO-CHOICE): cost-effectiveness thresholds. Accessed December 10, 2013 [http://www.who.int/choice/costs/CER_thresholds/en/index.html webcite]
• [25]International Monetary Fund (IMF): World Economic Outlook Database. Accessed December 10, 2013 [http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx webcite]
• [26]Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, Hatzikou M, Alexopoulosi D: Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Hellenic J Cardiol 2005, 46:212-221.
• [27]National Institute for Health and Clinical Excellence (NICE): Guidance on the Use of long-Acting Insulin Analogues for the treatment of Diabetes-Insulin Glargine (TA53). Accessed September 30, 2013 [http://guidance.nice.org.uk/TA53/Guidance/pdf/English webcite]
• [28]Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M, Group L-D-S: Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care 2012, 35:1986-1993.
• [29]Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M, Group L-D-S: One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011, 65:397-407.
• [30]Lee WC, Samyshkin Y, Langer J, Palmer JL: Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ 2012, 15(Suppl 2):28-37.
• [31]Mezquita Raya P, Perez A, Ramirez de Arellano A, Briones T, Hunt B, Valentine WJ: Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther 2013, 4:417-430.
• [32]Lee WC, Conner C, Hammer M: Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther 2010, 32:1756-1767.
• [33]Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M: Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther 2011, 33:1698-1712.
• [34]Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
• [35]Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
• [36]Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.